Modality
ERT
MOA
JAK1i
Target
PD-1
Pathway
Wnt
Cervical CaOvarian CaCKD
Development Pipeline
Preclinical
~Dec 2014
→ ~Mar 2016
Phase 1
~Jun 2016
→ ~Sep 2017
Phase 2
Dec 2017
→ Nov 2031
Phase 2Current
NCT07541605
1,824 pts·CKD
2018-06→2030-10·Completed
NCT08267545
1,042 pts·Cervical Ca
2017-12→2031-11·Recruiting
2,866 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-10-237mo awayConference· CKD
2030-10-024.5y awayPh2 Data· CKD
2031-11-045.6y awayPh2 Data· Cervical Ca
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P2
Recruit…
P2
Complet…
Catalysts
Conference
2026-10-23 · 7mo away
CKD
Ph2 Data
2030-10-02 · 4.5y away
CKD
Ph2 Data
2031-11-04 · 5.6y away
Cervical Ca
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07541605 | Phase 2 | CKD | Completed | 1824 | SeizFreq |
| NCT08267545 | Phase 2 | Cervical Ca | Recruiting | 1042 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| MRN-8133 | Moderna | Phase 2 | PD-1 | |
| ARG-1924 | Argenx | Preclinical | DLL3 | |
| Semazasiran | BeiGene | Phase 1 | PD-1 | |
| Rimainavolisib | Illumina | Phase 2 | PD-1 | |
| ROI-1081 | Roivant Sciences | Phase 1/2 | PI3Kα | |
| Motanaritide | Intellia | Approved | PD-1 | |
| 450-8514 | Astellas | Phase 3 | RET |